Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12 - 18 November 2023 and includes updates on SARS-CoV-2 variant classification, West Nile virus, multistate outbreak of salmonella, and an overview of respiratory virus epidemiology in the EU/EEA.
This report describes and summarises the results of the 2022 external quality assessment (EQA) of antimicrobial susceptibility testing (AST) by clinical laboratories that participate in the European Antimicrobial Resistance Surveillance Network (EARS-Net).
In 2022, for the first time, all European Union/European Economic Area (EU/EEA) countries reported data to the European Antimicrobial Resistance Surveillance Network (EARS-Net).
For 2022, 29 countries (27 European Union (EU) Member States and two European Economic Area (EEA) countries – Iceland and Norway) reported data on antimicrobial consumption.
This executive summary showcases results derived from 2022 antimicrobial resistance (AMR) data, sourced from invasive isolates reported to both the Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) network and the European Antimicrobial Resistance Surveillance Network (EARS-Net).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 5 - 11 November 2023 and includes updates on SARS-CoV-2 variants, an overview of respiratory virus epidemiology in the EU/EEA, West Nile Virus, measles, diphtheria, Middle East respiratory virus syndrome, chikungunya, and dengue.